ACE2 News and Research

RSS

Census of viral spike protein antigens could benefit development of SARS-CoV-2 therapeutics

A group of researchers has determined how different proteins associated with SARS-CoV-2 - the virus that causes COVID-19 - generate immune responses when given to rabbits as immunizations.

8 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

SARS-CoV-2 infection causes specific kidney proximal tubular injury

SARS-CoV-2-associated acute kidney injury (AKI) is one of the more frequently encountered organ involvements in COVID-19 - in as many as 80% of critically ill patients, according to a recent study.

8 Jun 2020

The receptor binding domain of the SARS-CoV-2

With the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across most of the world, scientists are working strenuously to find effective therapies or vaccines. Most strategies being worked on at present are targeting viral entry into the host cells, mainly through the interaction of the SARS-CoV-2 S protein with the angiotensin-converting enzyme 2 (ACE2) receptor.

8 Jun 2020

Inhibition of coronavirus spike protein binding to ACE2

A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.

8 Jun 2020

SARS-CoV-2 invasion of central nervous system through olfactory tract

As the COVID-19 pandemic continues to claim lives throughout the world, the evidence is mounting that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract as well as the central nervous system. Now, a new study by German researchers published on the preprint server bioRxiv in June 2020 describes various neurological manifestations of COVID-19, as well as the underlying pathophysiology.

7 Jun 2020

New strategy may facilitate development of multi-epitope peptide vaccine against SARS-CoV-2

By combining T and B lymphocyte analysis with manufacturability heuristic, researchers from the US and Germany proposed a set of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine peptides to use in subsequent animal studies and clinical trials. Their paper is currently available on the bioRxiv preprint server.

7 Jun 2020

Designing a prototype spike protein vaccine for SARS-CoV-2

A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.

4 Jun 2020

SARS-CoV-2 gene deletions may cause milder infections and increase human-to-human transmission

In their recent paper released on the bioRxiv preprint server, a research group from Spain demonstrated how genome changes and deletions in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could represent a strategy of natural selection used for lessening the impact of infection in order to increase viral transmission potential.

4 Jun 2020

Alpaca-derived antiviral agent neutralizes SARS-CoV-2

Researchers at Karolinska University Hospital and the University of Cape Town have identified an antibody fragment that targets the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and potently neutralizes the virus.

4 Jun 2020

Potential new immunotherapy for critical COVID-19

Researchers at the Chongqing Medical University in China have identified a cytokine that could serve as a potential candidate for treating patients with severe coronavirus disease 2019 (COVID-19).

4 Jun 2020

COVID-19 can increase stroke risk in young healthy people

Young patients with no risk factors for stroke may have an increased risk if they have contracted COVID-19, whether or not they are showing symptoms of the disease.

4 Jun 2020

Blood group type may affect susceptibility to COVID-19 respiratory failure

A group of over 120 researchers from various institutions across Europe has performed the first genome-wide association study to reveal host genetic factors that may contribute to respiratory failure in cases of coronavirus disease 209 (COVID-19).

3 Jun 2020

Scientists map how SARS-CoV-2 infects the airways

Now, in a significant scientific study, a team of researchers at the University of North Carolina Health Care (UNC) have mapped how SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19), infects the nasal cavity, the airways, and down to the lungs.

3 Jun 2020

Does smoking increase COVID-19 risk?

The COVID-19 pandemic continues to smolder and smoke in many parts of the world, with over 100,000 cases, and more than 3,000 deaths reported every day. Many factors are responsible for the higher risk of infection in certain specific population subgroups are known.

2 Jun 2020

Study shows Sofosbuvir alleviates COVID-19-related neurological symptoms

A group of researchers has studied the effects of an antiviral drug Sofosbuvir on human brain organoids infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Jun 2020

SARS-CoV-2 can adversely affect cardiac cells and heart function

A research group from Germany demonstrated a direct toxic effect of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on cardiac cells in their paper published on the bioRxiv* preprint server. The finding warrants an in-depth analysis of cardiac tissue in certain coronavirus disease (COVID-19) patients, as well as close monitoring for any direct cardiomyocyte injury.

2 Jun 2020

Specific immune suppression leads to severe COVID-19 disease

A new study published online on the preprint server medRxiv in May 2020 reports that specific changes in the way the human immune system responds to COVID-19 determine whether the individual develops moderate or severe illness.

2 Jun 2020

SARS-CoV-2 emergence could be due to genetic selection and recombination

Researchers have found that genetic selection and recombination could be behind the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that leads to acute respiratory distress syndrome (ARDS) or COVID-19 disease. This research could explain COVID-19 pandemic and its emergence. The study titled, “Emergence of SARS-CoV-2 through recombination and strong purifying selection,” was published in the journal Science Advances.

1 Jun 2020

Study maps novel coronavirus infection in cells of nasal cavity, airway and lungs

In a major scientific study published in the journal Cell, scientists at the UNC School of Medicine and the UNC Gillings School of Global Public Health have characterized the specific ways in which SARS-CoV-2 – the coronavirus that causes COVID-19 – infects the nasal cavity to a great degree – replicating specific cell types – and infects and replicates progressively less well in cells lower down the respiratory tract, including the lungs.

1 Jun 2020